Pfizer India Shares Jump 11% After Declaring Record Dividend for FY25

On May 20, 2025, Pfizer share price soared over 11%, reaching a day high of ₹4,995.85 at 11:50 AM, after opening at ₹4,698.80 on BSE.  The gain in Pfizer share price follows the release of robust earnings for the March quarter and declaration of its largest dividend payout in over a decade.

To mark its 75th year of operations in India, Pfizer’s board announced a final dividend of ₹35 per share and a special commemorative dividend of ₹100 per share. In addition, shareholders will receive a further special dividend of ₹30 per share, stemming from profits generated through the transfer of a leasehold land and its associated building.

Altogether, this brings the total dividend payout to ₹165 per share. The company has set July 9, 2025, as the record date for determining eligible shareholders. This marks Pfizer’s most generous dividend since May 2020, when the company announced a special dividend of ₹320 per share.

Pfizer Dividend History

Pfizer has consistently paid dividends over the years, with recent distributions reflecting its commitment to shareholders. On August 21, 2024, the company declared a final dividend of ₹35. Previously, Pfizer issued a final dividend of ₹40 on August 11, 2023. Additionally, a special dividend of ₹30 was paid on September 19, 2022, followed by another final dividend of ₹35 on August 18, 2022. These payments highlight Pfizer's strong financial position and its ongoing efforts to reward investors.

Also Read: Key Corporate Actions This Week (May 19–23): Ashok Leyland, LTIMindtree, Havells to Go Ex-Dividend This Week

Pfizer Q4FY25 Earnings Highlights

The company posted an 8% year-on-year increase in revenue for the March quarter. More notably, EBITDA jumped 20% year-on-year and saw a 56% sequential rise from the December quarter. EBITDA margin also improved significantly, expanding by 11 percentage points to 38.4%, compared to 27.1% in the same quarter last year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.